BANK VONTOBEL/CALL/NOVO NORDISK ADR B/155/0.1/21.03.25 | Market Closed - Börse Stuttgart 12:02:21 17/05/2024 pm IST | ||
| 0.9 EUR | -4.26% |
|
| Current month | +5.88% | ||
| 1 month | +13.92% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 17/24/17 | 0.9 | -4.26% |
| 16/24/16 | 0.94 | +2.17% |
| 15/24/15 | 0.92 | +1.10% |
| 14/24/14 | 0.91 | +16.67% |
| 13/24/13 | 0.78 | 0.00% |
Delayed Quote Börse Stuttgart
Last update May 17, 2024 at 12:02 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Vontobel
|
| WKN | VD3N4R |
| ISIN | DE000VD3N4R2 |
| Date issued | 08/04/2024 |
| Strike | 155 $ |
| Maturity | 21/03/2025 (306 Days) |
| Parity | 10 : 1 |
| Emission price | 0.83 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.99 € |
|---|---|
| Lowest since issue | 0.68 € |
| Spread | 0.01 € |
| Spread % | 1.16% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
903.3
DKK
Average target price
909.2
DKK
Spread / Average Target
+0.66%
- Stock Market
- Warrants
- Warrant
